| 義守大學 |
2010-05 |
Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design
|
Jyh-Ming Liou; Jaw-Town Lin; Chi-Yang Chang;Mei-Jyh Chen;Tsu-Yao Cheng; Yi-Chia Lee; Chien-Chuan Chen;Wang-Huei Sheng;Hsiu-Po Wang;Ming-Shiang Wu |
| 國立臺灣大學 |
2010 |
Levofloxacin-Based and Clarithromycin-Based Triple Therapies as First-Line and Second-Line Treatments for Helicobacter Pylori Infection: A Randomised Comparative Trial with Crossover Design
|
劉志銘; 林肇堂; 張吉仰; 陳美志; 鄭祖耀; 李宜家; 陳建全; 盛望徽; 王秀伯; 吳明賢; LIOU, JYH-MING; LIN, JAW-TOWN; CHANG, CHI-YANG; CHEN, MEI-JYH; CHENG, TSU-YAO; LEE, YI-CHIA; CHEN, CHIEN-CHUAN; SHENG, WANG-HUEI; WANG, HSIU-PO; WU, MING-SHIANG |
| 臺大學術典藏 |
2018-09-10T08:04:12Z |
Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: A randomised comparative trial with crossover design
|
Liou, J.-M. and Lin, J.-T. and Chang, C.-Y. and Chen, M.-J. and Cheng, T.-Y. and Lee, Y.-C. and Chen, C.-C. and Sheng, W.-H. and Wang, H.-P. and Wu, M.-S.; TSU-YAO CHENG; JYH-MING LIOU; WANG-HUEI SHENG; YI-CHIA LEE; MING-SHIANG WU |
| 臺大學術典藏 |
2022-02-18T08:46:59Z |
Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: A randomised comparative trial with crossover design
|
Liou J.-M.; Lin J.-T.; Chang C.-Y.; Chen M.-J.; Cheng T.-Y.; Lee Y.-C.; CHIEN-CHUAN CHEN; Sheng W.-H.; Wang H.-P.; Wu M.-S. |
| 臺大學術典藏 |
2020-11-02T02:04:55Z |
Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: A randomised comparative trial with crossover design
|
MING-SHIANG WU; Wang H.-P.; Sheng W.-H.; Chen C.-C.; Lee Y.-C.; Cheng T.-Y.; Liou J.-M.; Lin J.-T.; Chang C.-Y.; Chen M.-J. |
| 臺大學術典藏 |
2021-01-15T03:47:07Z |
Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: A randomised comparative trial with crossover design
|
Liou J.-M.; Lin J.-T.; Chang C.-Y.; Chen M.-J.; Cheng T.-Y.; Lee Y.-C.; Chen C.-C.; Sheng W.-H.; HSIU-PO WANG; Wu M.-S. |
| 臺大學術典藏 |
2021-02-02T02:21:49Z |
Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: A randomised comparative trial with crossover design
|
Liou J.-M.; Lin J.-T.; Chang C.-Y.; Chen M.-J.; Cheng T.-Y.; Lee Y.-C.; Chen C.-C.; Sheng W.-H.; Wang H.-P.; MING-SHIANG WU |
| 臺大學術典藏 |
2021-02-26T02:00:08Z |
Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: A randomised comparative trial with crossover design
|
Liou J.-M.;Lin J.-T.;Chang C.-Y.;Chen M.-J.;Cheng T.-Y.;Lee Y.-C.;Chen C.-C.;Wang-Huei Sheng;Wang H.-P.;Wu M.-S.; Liou J.-M.; Lin J.-T.; Chang C.-Y.; Chen M.-J.; Cheng T.-Y.; Lee Y.-C.; Chen C.-C.; WANG-HUEI SHENG; Wang H.-P.; Wu M.-S. |
| 臺大學術典藏 |
2021-05-27T08:21:01Z |
Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: A randomised comparative trial with crossover design
|
JYH-MING LIOU; Lin J.-T.; Chang C.-Y.; Chen M.-J.; Cheng T.-Y.; Lee Y.-C.; Chen C.-C.; Sheng W.-H.; Wang H.-P.; Wu M.-S. |
| 臺大學術典藏 |
2021-02-02T05:45:36Z |
Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: A randomised comparative trial with crossover design
|
Liou J.-M.;Lin J.-T.;Chang C.-Y.;Chen M.-J.;Cheng T.-Y.;Yi-Chia Lee ;Chen C.-C.;Sheng W.-H.;Wang H.-P.;Wu M.-S.; Liou J.-M.; Lin J.-T.; Chang C.-Y.; Chen M.-J.; Cheng T.-Y.; YI-CHIA LEE; Chen C.-C.; Sheng W.-H.; Wang H.-P.; Wu M.-S. |
| 臺大學術典藏 |
2021-02-18T08:38:13Z |
Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: A randomised comparative trial with crossover design
|
Liou J.-M.; Lin J.-T.; Chang C.-Y.; Chen M.-J.; Cheng T.-Y.; Lee Y.-C.; CHIEN-CHUAN CHEN; Sheng W.-H.; Wang H.-P.; Wu M.-S. |
| 臺大學術典藏 |
2021-03-10T07:09:15Z |
Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: A randomised comparative trial with crossover design
|
Liou J.-M.;Lin J.-T.;Chang C.-Y.;Chen M.-J.;Tsu-Yao Cheng;Lee Y.-C.;Chen C.-C.;Sheng W.-H.;Wang H.-P.;Wu M.-S.; Liou J.-M.; Lin J.-T.; Chang C.-Y.; Chen M.-J.; TSU-YAO CHENG; Lee Y.-C.; Chen C.-C.; Sheng W.-H.; Wang H.-P.; Wu M.-S. |
| 臺大學術典藏 |
2022-09-06T07:43:23Z |
Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: A randomised comparative trial with crossover design
|
Liou J.-M.; Lin J.-T.; Chang C.-Y.; Chen M.-J.; Cheng T.-Y.; Lee Y.-C.; Chen C.-C.; Sheng W.-H.; Wang H.-P.; MING-SHIANG WU |
| 國立成功大學 |
2007-08 |
Levofloxacin-containing triple therapy to eradicate the persistent H. pylori after a failed conventional triple therapy
|
Cheng, Hsiu-Chi; Chang, Wei-Lun; Chen, Wei-Ying; Yang, Hsiao-Bai; Wu, Jiunn-Jong; Sheu, Bor-Shyang |
| 國家衛生研究院 |
2014-08 |
Levofloxacin-resistant Haemophilus influenzae, Taiwan, 2004-2010
|
Kuo, SC;Chen, PC;Shiau, YR;Wang, HY;Lai, JF;Huang, IW;Yang Lauderdale, TL |
| 國立成功大學 |
2022-07 |
Levosimendan Administration May Provide More Benefit for Survival in Patients with Non-Ischemic Cardiomyopathy Experiencing Acute Decompensated Heart Failure
|
Lee;Wei-Chieh;Wu;Po-Jui;Fang;Hsiu-Yu;Fang;Yen-Nan;Chen;Huang-Chung;Tong;Meng-Shen;Sung;Pei-Hsun;Lee;Chieh-Ho;Chung;Wen-Jung |
| 臺北醫學大學 |
2014 |
Levosimendan attenuates multiple organ injury and improves survival in peritonitis-induced septic shock: studies in a rat model
|
CM, Tsao;KY, Li;SJ, Chen;SM, Ka;WJ, Liaw;HC, Huang;CC, Wu |
| 臺北醫學大學 |
2014 |
Levosimendan attenuates multiple organ injury and improves survival in peritonitis-induced septic shock: studies in a rat model
|
Tsao, CM;Li, KY;Chen, SJ;Ka, SM;Liaw, WJ;Huang, HC;Wu, CC |
| 國立交通大學 |
2020-02-02T23:54:34Z |
Levosimendan shortens action potential duration, decreases alternans threshold and prevents ventricular arrhythmia during therapeutic hypothermia in isolated rabbit hearts
|
Hsieh, Y. C.; Li, C. H.; Liao, Y. C.; Lin, J. C.; Weng, C. J.; Lin, S. F.; Huang, J. L.; Wu, T. J. |
| 國立臺灣科技大學 |
2016 |
Levulinic acid from corncob by subcritical water process
|
Hartono, C.D;Marlie, K.J;Putro, J.N;Soetardjo, F.E;Ju, Y.H;Sirodj, D.A.N;Ismadji, S. |
| 國立成功大學 |
2014 |
Levulinic acid production from Cicer arietinum, cotton, Pinus radiata and sugarcane bagasse
|
Victor, Amudhavalli; Pulidindi, Indra Neel; Gedanken, Aharon |
| 國立交通大學 |
2014-12-13T10:30:15Z |
Levy模型下無限期美式選擇權的定價
|
許元春; SHEU YUAN-CHUNG |
| 國立交通大學 |
2015-01-12T12:52:55Z |
Lévy與GARCH-Lévy過程之選擇權評價與實證分析：台灣加權股價指數選擇權為例
|
吳仰哲; 廖四郎; 林士貴; Yang-Che Wu; Szu-Lang Liao; Shih-Kuei Lin |
| 國立政治大學 |
2010-01 |
Lévy與GARCH-Lévy過程之選擇權評價與實證分析：台灣加權股價指數選擇權為例
|
林士貴; Lin, Shih-Kuei; 吳仰哲; Lin, S. K.; Wu, Yang-Che; 廖四郎; Liao, Szu-Lang |
| 國立政治大學 |
2010-01 |
Lévy與GARCH-Lévy過程之選擇權評價與實證分析：臺灣加權股價指數選擇權為例
|
吳仰哲;廖四郎;林士貴; Wu, Yang-Che ; Liao, Szu-Lang ; Lin, Shih-Kuei |
